{"filing":{"accession_number":"0001193125-26-342524","cik":"0001528115","ticker":"ANNX","company_name":"Annexon, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d130710d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/d130710d8k.htm"},"events":[{"id":26671,"run_id":24244,"accession_number":"0001193125-26-342524","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Annexon appointed Mark S. Blumenkranz, M.D., M.M.S. to its board of directors effective August 10, 2026, and assigned him to the Audit Committee and Science and Technology Committee. Dr. Blumenkranz brings significant expertise in retinal disease and biotechnology leadership to support the company's late-stage clinical programs.","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27876,"accession_number":"0001193125-26-342524","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Mark S. Blumenkranz, M.D., M.M.S. to Annexon's board of directors effective August 10, 2026, along with his appointment to the Audit Committee and Science and Technology Committee. While the section also mentions Muneer Satter's concurrent resignation after 11 years of service, the primary action disclosed is the appointment of a new director with significant expertise in retinal disease and biotechnology leadership, which is material to investors assessing board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:25.866618+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27877,"accession_number":"0001193125-26-342524","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a board departure (Muneer Satter stepping down after 11 years) and a board appointment (Dr. Mark S. Blumenkranz joining the board). While both events are mentioned, the press release emphasizes the appointment of Dr. Blumenkranz as the principal action, highlighting his extensive expertise in retinal disease and biotechnology leadership as strategic value for the company's advancement of late-stage clinical programs. The appointment of a highly qualified director with relevant domain expertise is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:25.866618+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27876,"accession_number":"0001193125-26-342524","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses the appointment of Mark S. Blumenkranz, M.D., M.M.S. to Annexon's board of directors effective August 10, 2026, along with his appointment to the Audit Committee and Science and Technology Committee. While the section also mentions Muneer Satter's concurrent resignation after 11 years of service, the primary action disclosed is the appointment of a new director with significant expertise in retinal disease and biotechnology leadership, which is material to investors assessing board composition and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:25.866618+00:00","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-10"},{"id":27877,"accession_number":"0001193125-26-342524","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both a board departure (Muneer Satter stepping down after 11 years) and a board appointment (Dr. Mark S. Blumenkranz joining the board). While both events are mentioned, the press release emphasizes the appointment of Dr. Blumenkranz as the principal action, highlighting his extensive expertise in retinal disease and biotechnology leadership as strategic value for the company's advancement of late-stage clinical programs. The appointment of a highly qualified director with relevant domain expertise is material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:39:25.866618+00:00","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-10"}]}